GT Biopharma Balance Sheet Health
Financial Health criteria checks 4/6
GT Biopharma has a total shareholder equity of $2.1M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $6.8M and $4.7M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$6.42m |
| Equity | US$2.10m |
| Total liabilities | US$4.66m |
| Total assets | US$6.76m |
Recent financial health updates
We're Keeping An Eye On GT Biopharma's (NASDAQ:GTBP) Cash Burn Rate
Jan 06
We Think GT Biopharma (NASDAQ:GTBP) Needs To Drive Business Growth Carefully
Sep 21Here's Why We're Watching GT Biopharma's (NASDAQ:GTBP) Cash Burn Situation
Jun 08Recent updates
We're Keeping An Eye On GT Biopharma's (NASDAQ:GTBP) Cash Burn Rate
Jan 06GT Biopharma files for $150M mixed shelf offering
Oct 13We Think GT Biopharma (NASDAQ:GTBP) Needs To Drive Business Growth Carefully
Sep 21GT Biopharma GAAP EPS of -$0.10 beats by $0.07
Aug 11Here's Why We're Watching GT Biopharma's (NASDAQ:GTBP) Cash Burn Situation
Jun 08Companies Like GT Biopharma (NASDAQ:GTBP) Are In A Position To Invest In Growth
Nov 24Getting To Know GT Biopharma
Jun 06GT Biopharma names Gregory Berk Chief Medical Officer
Apr 26Financial Position Analysis
Short Term Liabilities: GTBP's short term assets ($6.8M) exceed its short term liabilities ($4.7M).
Long Term Liabilities: GTBP has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: GTBP is debt free.
Reducing Debt: GTBP currently has no debt however we can't compare to 5 years ago as we have no data for that period.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: GTBP has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: GTBP has less than a year of cash runway if free cash flow continues to reduce at historical rates of 10.9% each year